A phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic study of PM00104 [Zalypsis] administered intravenously over 1 hour daily for 5 days, every 3 weeks, to subjects with advanced malignant solid tumors or lymphoma

Trial Profile

A phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic study of PM00104 [Zalypsis] administered intravenously over 1 hour daily for 5 days, every 3 weeks, to subjects with advanced malignant solid tumors or lymphoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2008

At a glance

  • Drugs PM 00104 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Oct 2008 Status changed from recruiting to discontinued, as reported by Clinicaltrials.gov.
    • 07 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top